Does digitoxin reduce the risk for all-cause mortality and/or hospital admission for worsening HF in patients with advanced chronic HFrEF on top of standard of care treatment?
The DIGIT-HF trial is designed to evaluate whether the addition of digitoxin to standard of care improves clinical outcomes in patients with advanced chronic HFrEF.
The DIGIT-HF trial will provide important evidence, whether the cardiac glycoside digitoxin reduces the risk for all-cause mortality and/or hospital admission for worsening HF in patients with advanced chronic HFrEF on top of standard of care treatment.
Bavendiek et al. (Wed,) studied this question.